SUMATRIPTAN (sumatriptan) by Design Pharmaceuticals is serotonin 1b receptor agonists [moa]. Approved for serotonin-1b and serotonin-1d receptor agonist [epc]. First approved in 2020.
Drug data last refreshed 19h ago
Serotonin 1b Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Worked on SUMATRIPTAN at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.